Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Synopsis

Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon-α in Blood

Sergio A. Hernández, Katarina Ogrinc, Miša Korva, Andrej Kastrin, Petra Bogovič, Tereza Rojko, Keith W. Kelley, Janis J. Weis, Franc Strle, and Klemen StrleComments to Author 
Author affiliations: Tufts University School of Medicine, Boston, Massachusetts, USA (S.A. Hernández, K. Strle); New York State Department of Health, Albany, New York, USA (S.A. Hernández, K. Strle); University Medical Center Ljubljana, Ljubljana, Slovenia (K. Ogrinc, P. Bogovič, T. Rojko, F. Strle}; University of Ljubljana, Ljubljana (M. Korva, A. Kastrin); University of Illinois, Urbana-Champaign, Illinois, USA (K.W. Kelley); University of Utah, Salt Lake City, Utah, USA (J.J. Weis)

Main Article

Table 2

Comparison of cytokine and chemokine levels in cerebrospinal fluid and serum at study entry and 3 mo for association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood, Slovenia *

Mediator
 T = 0, n = 719
T = 3 mo, n = 64
Median CSF (range), pg/mL
 Median serum (range), pg/mL
 p value†
 Median CSF (range), pg/mL
 Median serum (range), pg/mL
 p value†
Innate
IFN-α 3 (0–64) 2 (0–187) 1 1 (0–19) 2 (0–158) 0.0001
IL-6 7 (0–146) 1 (0–234) 0.0002 1 (0–1) 1 (0–88) 0.1
IL-10 6 (0–422) 1 (0–40) 0.0002 1 (0–1) 1 (0–3) 1
IL-8 144 (18–1,288) 23 (0–2,159) 0.0002 31 (13–107) 15 (1–1,700) 0.0002
TNF 10 (0–150) 20 (2–385) 0.0002 2 (0–20) 19 (2–278) 0.0001
CCL2 1,096 (223–48,494) 668 (60–1,579) 0.0002 719 (241–1,889) 688 (287–7,311) 0.3
CCL3 49 (1–107) 25 (1–1,310) 0.003 38 (1–87) 21 (1–1080) 0.0001
CCL4
 29 (1–787)
 127 (29–2,567)
 0.0002
11 (1–35)
 129 (33–1,223)
 0.0001
TH1 adaptive
IFN-γ 2 (0–193) 3 (0–349) 1 1 (0–11) 1 (0–32) 0.0001
CXCL9 2,274 (14–37,051) 1,175 (49–26,310) 0.05 117 (1–1,997) 853 (110–20,472) 0.0001
CXCL10 16,920 (137–139,804) 600 (66–4,484) 0.0002 905 (201–16,407) 439 (50–6,221) 0.0001
CXCL11 80 (1–2,640) 45 (1–534) 0.003 10 (1–86) 46 (1–499) 0.0001
CCL19 55 (10–1,598) 54 (10–939) 0.5 10 (3–362) 73 (7–1,730) 0.0001
IL-12p70
 3 (1–17)
 3 (1–1,486)
 0.5
1 (1–3)
 3 (1–45)
 0.0001
TH17 adaptive
IL-17a 9 (4–25) 4 (0–347) 0.0002 7 (3–11) 5 (1–64) 0.0001
IL-21 3 (3–11) 3 (3–229) 0.5 20 (1–20) 20 (3–41) 0.1
IL-23 3 (3–408) 13 (0–13,296) 0.007 49 (0–85) 49 (0–2,123) 0.02
CCL21
 530 (312–927)
 97 (20–1,473)
 0.0002
530 (256–1,222)
 98 (20–1,323)
 0.0001
B-cell adaptive
CXCL12 3,760 (98–27,479) 2,875 (98–16,039) 0.006 1,953 (98–6,880) 2,875 (98–16,039) 0.02
CXCL13 187 (1–107,723) 18 (5–172) 0.0002 4 (1–62) 13 (1–151) 0.0001

*Bold indicates statistically significant p values. CCL, CC motif chemokine ligand; CSF, cerebrospinal fluid; CXCL, CXC motif chemokine ligand; IFN, interferon; IL, interleukin; T, timepoint (0 indicates baseline); TNF, tumor necrosis factor. †Benjamini-Hochberg corrected (false discovery rate = 0.05).

Main Article

Page created: March 23, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external